Modular design of optically controlled protein affinity reagents

2018 ◽  
Vol 54 (13) ◽  
pp. 1591-1594 ◽  
Author(s):  
A. Babalhavaeji ◽  
G. A. Woolley

Reversible, optical control of a generalizable protein affinity reagent.

2009 ◽  
Vol 131 (47) ◽  
pp. 17233-17241 ◽  
Author(s):  
Berea A. R. Williams ◽  
Chris W. Diehnelt ◽  
Paul Belcher ◽  
Matthew Greving ◽  
Neal W. Woodbury ◽  
...  

2009 ◽  
Vol 9 (1) ◽  
pp. 1-10 ◽  
Author(s):  
David E. Gloriam ◽  
Sandra Orchard ◽  
Daniela Bertinetti ◽  
Erik Björling ◽  
Erik Bongcam-Rudloff ◽  
...  

2016 ◽  
Vol 13 (10) ◽  
pp. 805-806 ◽  
Author(s):  
Seth Blackshaw ◽  
Anand Venkataraman ◽  
Jose Irizarry ◽  
Kun Yang ◽  
Stephen Anderson ◽  
...  

2016 ◽  
Vol 110 (3) ◽  
pp. 539a
Author(s):  
Amirhossein Babalhavaeji ◽  
Mingxin Dong ◽  
Di Wu ◽  
G. Andrew Woolley

2021 ◽  
Author(s):  
Shunsuke Onogi ◽  
Shih-Hui Lee ◽  
Krista R. Fruehauf ◽  
Kenneth J. Shea

2010 ◽  
Vol 28 (7) ◽  
pp. 650-653 ◽  
Author(s):  
Julie Bourbeillon ◽  
Sandra Orchard ◽  
Itai Benhar ◽  
Carl Borrebaeck ◽  
Antoine de Daruvar ◽  
...  

1999 ◽  
Vol 78 (3) ◽  
pp. 113-116 ◽  
Keyword(s):  

Author(s):  
D. Fontani ◽  
P. Sansoni ◽  
S. Coraggia ◽  
L. Mercatelli ◽  
D. Jafrancesco ◽  
...  
Keyword(s):  

Author(s):  
Martin Reynders ◽  
Bryan Matsuura ◽  
Marleen Bérouti ◽  
Daniele Simoneschi ◽  
Antonio Marzio ◽  
...  

<p><i>PROTACs (proteolysis targeting chimeras) are bifunctional molecules that tag proteins for ubiquitylation by an E3 ligase complex and subsequent degradation by the proteasome. They have emerged as powerful tools to control the levels of specific cellular proteins and are on the verge of being clinically used. We now introduce photoswitchable PROTACs that can be activated with the temporal and spatial precision that light provides. These trifunctional molecules, which we named PHOTACs, consist of a ligand for an E3 ligase, a photoswitch, and a ligand for a protein of interest. We demonstrate this concept by using PHOTACs that target either BET family proteins (BRD2,3,4) or FKBP12. Our lead compounds display little or no activity in the dark but can be reversibly activated to varying degrees with different wavelengths of light. Our modular and generalizable approach provides a method for the optical control of protein levels with photopharmacology and could lead to new types of precision therapeutics that avoid undesired systemic toxicity.</i><b></b></p>


Sign in / Sign up

Export Citation Format

Share Document